Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors’ Liability Premiums
  • Florida’s KidCare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors' Liability Premiums
  • Florida’s KidCare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Feb 15 2018

Full Issue

During A Nasty Flu Season, Promising Drug That Kills The Virus Is On Horizon

A Japanese company says its drug reduced influenza viral load to undetectable levels within 24 hours for more than half of the 414 participants in a study. Tamiflu similarly killed the virus, but only in 9 percent of its participants, the company said.

CNN: Flu Warfare May Look Different Next Year

New ways of preventing and treating the flu are on the horizon. One experimental treatment developed by researchers in Japan has garnered plenty of attention, but only time will tell whether or not the drug is worthy of whole-hearted enthusiasm. In October, Shionogi & Co. Ltd., based in Osaka, reported that its experimental drug baloxavir marboxil reduced influenza viral load to undetectable levels -- killed the virus -- within 24 hours for more than half of the 414 participants in a study. (Scutti, 2/14)

In other news on the flu —

The Washington Post: Tracking The Flu Week By Week

This flu season is turning out to be so intense that the number of people seeking care at doctors' offices and emergency rooms has surged to levels not reported since the peak of the 2009 swine flu pandemic, federal officials said Feb. 9. This year's vaccine is less effective against the strain of virus making the rounds. But there's another factor that gives aggressive viruses such as this one an extra punch in the United States: lack of access to paid sick time. (Cameron and Keating, 2/14)

The Associated Press: Flu Kills First Delaware Woman Without Underlying Illness

Delaware health officials say the flu has killed the first person in the state who didn't have an underlying condition. The New Journal of Wilmington reports the 47-year-old woman who died this week did not have this year's flu shot and was infected with influenza B. The 10 other Delawareans who have died from the flu all had underlying conditions; Six of them had received a flu shot. (2/15)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF